Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2025
Product Development
A week of endpoint misses and trial halts: BioCentury’s Clinical Report
Bright spot was a slight rise in Protagonist shares on polycythemia vera results
BioCentury | Feb 6, 2024
Deals
Deals roundup: Novo boosts obesity manufacturing with Catalent buy
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
BioCentury | Nov 3, 2022
Management Tracks
Fantaccini becomes head of medical affairs, CSO at Novartis
Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra
BioCentury | Apr 15, 2022
Regulation
Protagonist’s Patel says rusfertide on track even as FDA move rattles investors
Agency reassessing breakthrough designation for polycythemia vera after adverse events
BioCentury | Apr 13, 2022
Deals
On heels of catalyst, Sierra picks GSK’s $1.9B takeout over ex-U.S. partnership
After signaling that an ex-U.S. deal was in the works, Sierra chose the M&A route, giving GSK global rights to a late-stage myelofibrosis candidate
BioCentury | Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
BioCentury | Oct 12, 2021
Product Development
Oct. 11 Quick Takes: Supernus diversifies CNS portfolio with Adamas acquisition
Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance
BioCentury | Sep 18, 2021
Deals
Sept. 17 Quick Takes: Clinical hold sinks Protagonist shares
Biocon partners with Serum Institute, plus Santé’s $260M fund, IASO Bio’s $108M series C, Everest in $12M renal deal and more
BioCentury | Mar 17, 2020
Finance
With strengthened balance sheet, Keros is latest biotech looking to test IPO market
Keros will look to fund ongoing clinical work via a listing that builds on this month’s series C round
BioCentury | Jan 29, 2020
Company News
Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more
Items per page:
1 - 10 of 67